title: Identification of two amino acids of the human cholecystokinin-A receptor that interact with the N-terminal moiety of cholecystokinin.
abstract: A region between residues 38 and 42 of the human cholecystokinin-A (CCK-A) receptor was shown to be involved in the binding of CCK but not in that of JMV 179 and JMV 180, two peptides closely related to CCK (Kennedy, K., Escrieut, C., Dufresne, M., Clerc, P., Vaysse, N., and Fourmy, D. (1995) Biochem. Biophys. Res. Commun. 213, 845-852). In the present study, we have identified the residues of both the receptor and the ligand responsible for this differential binding. Residues Trp-39 and Gln-40 of the receptor were crucial for binding of the C-terminal nonapeptide of CCK as W39F and Q40N mutants demonstrated parallel decreases in both affinity and potency to induce accumulation of inositol phosphates (12.9- and 20.9-fold). The W39F and Q40N mutant receptors bound CCK analogues modified at their C-terminal end, including JMV 179 and JMV 180, as well as the C-terminal amidated heptapeptide of CCK, with identical affinities to the wild-type receptor. In contrast, W39F and Q40N mutants bound CCK octapeptide with the same decreased affinity as the CCK nonapeptide. The modeling of the CCK-A receptor and the docking of the peptide agonists [Thr,Nle]CCK9 and CCK-8 indicated that their N terminus was connected to the receptor through a strong bond network involving Trp-39 and Gln-40 thus confirming experimental data. These first molecular data identifying the agonist binding site of the human CCK-A receptor represent an important step toward the complete delineation of the agonist binding site and the understanding of the molecular mechanisms that govern differential activation of this receptor by CCK-related peptides.
authors.affiliation: INSERM U151, Institut Louis Bugnard, CHU Rangueil, Bat. L3, 31054 Toulouse Cedex, France.
authors.forename: K
authors.initials: K
authors.lastname: Kennedy
authors.forename: V
authors.initials: V
authors.lastname: Gigoux
authors.forename: C
authors.initials: C
authors.lastname: Escrieut
authors.forename: B
authors.initials: B
authors.lastname: Maigret
authors.forename: J
authors.initials: J
authors.lastname: Martinez
authors.forename: L
authors.initials: L
authors.lastname: Moroder
authors.forename: D
authors.initials: D
authors.lastname: Fréhel
authors.forename: D
authors.initials: D
authors.lastname: Gully
authors.forename: N
authors.initials: N
authors.lastname: Vaysse
authors.forename: D
authors.initials: D
authors.lastname: Fourmy
mesh_terms: D000595:Amino Acid Sequence; D000818:Animals; D001665:Binding Sites; D001667:Binding, Competitive; D019556:COS Cells; D002462:Cell Membrane / Q000378:metabolism; D002766:Cholecystokinin / Q000737:chemistry / Q000378:metabolism*; D003198:Computer Simulation; D005973:Glutamine; D006727:Hormone Antagonists / Q000378:metabolism; D006801:Humans; D007700:Kinetics; D008024:Ligands; D008961:Models, Structural; D008969:Molecular Sequence Data; D016297:Mutagenesis, Site-Directed; D017354:Point Mutation; D011487:Protein Conformation; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin / Q000737:chemistry* / Q000378:metabolism*; D011993:Recombinant Fusion Proteins / Q000737:chemistry / Q000378:metabolism; D012844:Sincalide / Q000031:analogs & derivatives / Q000378:metabolism; D014162:Transfection; D014364:Tryptophan
chemical_list: D006727:Hormone Antagonists; D008024:Ligands; D043886:Receptor, Cholecystokinin A; D011949:Receptors, Cholecystokinin; D011993:Recombinant Fusion Proteins; D005973:Glutamine; C070096:JMV 179; C058451:JMV 180; D014364:Tryptophan; D002766:Cholecystokinin; D012844:Sincalide